Mirae Asset Mutual Fund raises stake in Symbiotec Pharmalab to 6.22%
- Mirae Asset Mutual Fund acquired 34,97,420 shares of Symbiotec Pharmalab Ltd
- The acquisition was executed via the open market on September 1, 2026
- Mirae Asset's total stake increased from 0.78% to 6.22% of total share capital
- The fund's diluted stake rose from 0.77% to 6.21%
- No warrants or convertible securities were part of this transaction
*this image is generated using AI for illustrative purposes only.
Mirae Asset Mutual Fund increased its stake in Symbiotec Pharmalab to 6.22% following an open market purchase of 34,97,420 shares on September 1, 2026. This acquisition represents a significant increase in the asset manager's exposure to the pharmaceutical company.
The transaction was disclosed under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Prior to this acquisition, Mirae Asset held 498,019 shares, representing 0.78% of the company's total share capital.
Acquisition Details
The fund acquired the additional shares through the open market mechanism. There were no warrants, convertible securities, or other instruments involved in this specific transaction. The acquisition did not involve any encumbrances such as pledges or liens.
| Metric | Before Acquisition | Acquired | After Acquisition |
|---|---|---|---|
| Shares Held | 498,019 | 3,497,420 | 3,995,439 |
| Stake (% Total) | 0.78% | 5.44% | 6.22% |
| Stake (% Diluted) | 0.77% | 5.44% | 6.21% |
Symbiotec Pharmalab's total equity share capital remained unchanged at 64,256,112 shares after the transaction. The total diluted share capital stands at 64,318,172 shares.
What the Numbers Show
The acquisition marks a substantial shift in institutional interest, with Mirae Asset increasing its position by more than eight times its previous holding. The jump from a sub-1% stake to over 6% indicates a decisive accumulation strategy by the mutual fund rather than incremental trading.
Historical Stock Returns for Symbiotec Pharmalab
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.48% | +5.26% | 0.0% | 0.0% | 0.0% | 0.0% |
What specific catalysts, such as upcoming clinical trial results or regulatory approvals, likely prompted Mirae Asset to aggressively increase its stake in Symbiotec Pharmalab?
How might this significant institutional accumulation influence Symbiotec's stock price volatility and liquidity in the near term?
Does this move signal a broader trend of mutual funds increasing exposure to mid-cap pharmaceutical companies amid current market conditions?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
